The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study

Department of Gynecologic Oncology, Academic Medical Centre, Amsterdam, The Netherlands.
European journal of obstetrics, gynecology, and reproductive biology (Impact Factor: 1.7). 04/2009; 144(1):80-4. DOI: 10.1016/j.ejogrb.2009.02.005
Source: PubMed


Low-grade endometrial stromal sarcoma (EES) is a rare tumour with a high recurrence rate but a very good prognosis. Responses to hormonal treatment of these recurrences have been published in case reports. The aim of this study was to determine the objective response rate and response duration of hormonal treatment for recurrent or residual low-grade ESS in a consecutive series of patients.
Thirteen consecutive patients with residual or recurrent disease were retrieved from the files. Eleven patients with measurable disease were treated with hormones and form the basis of this study. The following data were collected: age, date of primary diagnosis, type of primary treatment, the presence and localization of residual or recurrent disease, type of treatment, response, duration of response and survival.
After hormonal treatment 9 (82%) patients showed an objective response (4 complete response; 5 partial response), one showed stable disease (26+ months) and one progressive disease. Response duration was from 4+ to 252+ months (median 48+ months).
Hormonal treatment for measurable residual or recurrent low-grade ESS has a high response rate and should be considered as the treatment of choice for patients in which recurrent disease cannot easily be resected.

31 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Presents a method for the design of an IIR digital filter with real coefficients that approximates an arbitrary complex-valued frequency response. The iterative procedure is characterized by desirable convergence properties and has been observed to yield substantially better filters than other approaches. The method has been designed to be robust, easy to implement, widely applicable, and extremely efficient. The computational requirement of the algorithm is O(N<sup>3</sup>) for the design of a filter with N coefficients
    Acoustics, Speech, and Signal Processing, 1994. ICASSP-94., 1994 IEEE International Conference on; 05/1994
  • [Show abstract] [Hide abstract]
    ABSTRACT: Most recent GaN-based HEMT technology has been focused toward microwave power applications. In this work, we report DC and RF characteristics of the first E-mode AlGaN/GaN HEMTs fabricated down to 0.2 μm gatelength, and having an f<sub>t</sub> reaching 25 GHz. Further improvement of E-mode GaN HEMTs could open potential applications for mixed-signal ICs with a high dynamic range.
    Device Research Conference, 2002. 60th DRC. Conference Digest; 02/2002
  • [Show abstract] [Hide abstract]
    ABSTRACT: There are many common features between uterine sarcomas - leiomyosarcoma, endometrial stromal sarcoma, undifferentiated endometrial sarcoma and adenosarcoma -with regards to course, therapy and follow-up, such as post-menopausal bleeding or additional premenopausal bleeding, as well as rapid growth. There is a new staging system according to FIGO and new therapy recommendations according to NCCN. Prior to therapy, imaging staging of the pelvis, abdomen and chest should be carried out due to the frequency with which metastases are found at the time of diagnosis. In the case of disease spread in uterine sarcomas and malignant mixed tumors, good supportive therapy is a possible therapy option instead of chemo- or radiotherapy. The approach - observation, surgery, lymphonodectomy, mono- or polychemotherapy, radiotherapy, hormone therapy - is chosen according to the extent of spread and the resection status. Neoadjuvant therapies are not as yet established.
    Der Pathologe 07/2009; 30(4):304-12. · 0.39 Impact Factor
Show more